References
- Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol.5(7), 560–570 (2005).
- Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res.47(5), 401–407 (2003).
- Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Ann. Rev. Biochem.73, 321–354 (2004).
- Im DS. Linking Chinese medicine and G-protein-coupled receptors. Trends Pharmacol. Sci.24(1), 2–4 (2003).
- Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett.554(1–2), 189–193 (2003).
- Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem.277(24), 21453–21457 (2002).
- Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature427(6972), 355–360 (2004).
- Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological significance. Biochim. Biophys. Acta1781(9), 477–482 (2008).
- Mehling M, Lindberg R, Raulf F et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology75(5), 403–410 (2010).
- Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol.33(2), 91–101 (2010).
- Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
- Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
- Collins W, Cohen J, O’Connor P et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: Integrated analyses of Phase 2 and 3 studies (P843). Mult. Scler.16(Suppl. 10), S295 (2010).
- Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355(11), 1124–1140 (2006).
- Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology74(24), 2022–2024 (2010).
- Leypoldt F, Munchau A, Moeller F, Bester M, Gerloff C, Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology72(11), 1022–1024 (2009).
- Oo ML, Chang SH, Thangada S et al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J. Clin. Invest.121(6), 2290–2300 (2011).
- Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat. Rev. Drug Discov.8(4), 297–307 (2009).
- Tolle M, Levkau B, Keul P et al. Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res.96(8), 913–920 (2005).
- Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol.28(3), 102–107 (2007).
- Payne SG, Oskeritzian CA, Griffiths R et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood109(3), 1077–1085 (2007).
- Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther.115(1), 84–105 (2007).